Literature DB >> 20814152

Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters.

Qiang Meng1, Qi Liu, Changyuan Wang, Huijun Sun, Taiichi Kaku, Yukio Kato, Kexin Liu.   

Abstract

Cefditoren, a third generation cephalosporin antibiotics, has been used in clinics extensively. Previous results have indicated that cefditoren is excreted into bile as unchanged form. To investigate whether canalicular membrane transporters of hepatocytes were involved in the biliary excretion of cefditoren, we examined the hepatobiliary disposition of cefditoren using probenecid, novobiocin and verapamil as inhibitors of Mrp2, Bcrp and P-gp respectively in perfused rat livers. The values for the hepatic extraction ratio had no statistical significance, whereas cumulative biliary excretion rates of cefditoren were significantly reduced to 43.8% and 79.5% over 25 min in the perfused probenecid and novobiocin rats, respectively. We further investigated the effects of cefditoren on the expression of hepatic transporters by RT-PCR and Western blot after oral administration of cefditoren one week. The expression levels of Mrp2, Bcrp, Oat2 mRNA were markedly increased, while P-gp and Oct1 mRNA were decreased. In concordance with RT-PCR results, Mrp2 expression level increased by Western blotting. These results indicate that Mrp2 and Bcrp may be involved in the biliary excretion of cefditoren. Cefditoren can up-regulate the expression levels of Mrp2, Bcrp and Oat2, and down-regulate P-gp and Oct1 mRNA expression. These results provide important data for drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20814152     DOI: 10.2133/dmpk.dmpk-09-rg-092

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  1 in total

1.  Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.

Authors:  Chaojun Xue; Changyuan Wang; Qi Liu; Qiang Meng; Huijun Sun; Xiaokui Huo; Xiaodong Ma; Zhihao Liu; Xiaochi Ma; Jinyong Peng; Kexin Liu
Journal:  Tumour Biol       Date:  2016-01-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.